Single Low Dose Tafenoquine to Reduce P. Falciparum Transmission in Mali (NECTAR2)

Exclusion Criteria

• •Age \< 12 years or \> 50 years
• •Women who are pregnant or lactating
• •Blood thick film negative for sexual stages of malaria
• •Detection of a non-P. falciparum species by microscopy
• •Previous reaction to study drugs / known allergy to study drugs
• •Signs of severe malaria, including hyperparasitemia (defined as asexual parasitemia \> 100,000 parasites / µL)
• •Signs of acute or chronic illness, including hepatitis
• •The use of other medication (with the exception of paracetamol and/or aspirin)
• •Consent not given
• •G6PD-deficiency by Carestart rapid diagnostic test or the OSMMR2000 G6PD qualitative test
• •Use of antimalarial drugs over the past 7 days (as reported by the participant)
• •The use of other medication (with the exception of paracetamol and/or aspirin)
• •Clinically significant illness (intercurrent illness e.g. pneumonia, pre-existing condition e.g. renal disease, malignancy or conditions that may affect absorption of study medication e.g. severe diarrhea or any signs of malnutrition as defined clinically)
• •Signs of hepatic injury (such as nausea and/or abdominal pain associated with jaundice) or known severe liver disease (i.e. decompensated cirrhosis, Child Pugh stage B or C)
• •Signs, symptoms or known renal impairment
• •Clinically significant abnormal laboratory values as determined by history, physical examination or routine blood chemistries and hematology values (laboratory guideline values for exclusion are hemoglobin \< 10 g/dL, platelets \< 50,000/μl, White Blood Cell count (WBC) \< 2000/μl, serum creatinine \>2.0mg/dL, or ALT or AST more than 3 times the upper limit of normal for age.
• •Family history of diseases leading to QT prolongation or recent treatment with drugs linked to QT prolongation
• •Blood transfusion in the last 90 days.
• •Consistent with the long half-life of tafenoquine, effective contraception should be continued for 5 half-lives (3 months) after the end of treatment.
• •History of psychiatric disorders